After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset ...

TotalEnergies has signed a Solar Power Operating Lease Agreement with South Korean pharmaceutical company Daehwa ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug ...

Despite the buzz around liver detoxes, experts say they're unnecessary. Johns Hopkins and Dr Joseph Salhab clarify that the ...

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to ...

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

Scientists from UCSD’s Sanford Stem Cell Institute are working in collaboration with Axiom Space and the JM Foundation on the ...

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.